Appili Cash from 2010 to 2026
| APLI Stock | CAD 0.02 0.01 33.33% |
Cash | First Reported 2018-03-31 | Previous Quarter 348.7 K | Current Value 212.8 K | Quarterly Volatility 4.7 M |
Macro event markers
Financial statement trends for Appili Therapeutics provide structured context on operating performance and capital structure. The series highlights drivers like Interest Income of 4.6 M, Depreciation And Amortization of 11.3 K or Interest Expense of 4.2 M and ratios such as Price To Sales Ratio of 40.48, Dividend Yield of 0.0 or Days Sales Outstanding of 5.7 K, complementing Appili Therapeutics Valuation and Volatility.
Appili | Cash |
Evaluating Appili Therapeutics's Cash across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Appili Therapeutics's fundamental strength.
Latest Appili Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Appili Therapeutics over the last few years. Cash refers to the most liquid asset of Appili Therapeutics, which is listed under current asset account on Appili Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Appili Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Appili Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Appili Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Appili Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Appili Cash Regression Statistics
| Arithmetic Mean | 3,218,093 | |
| Geometric Mean | 1,914,025 | |
| Coefficient Of Variation | 105.90 | |
| Mean Deviation | 2,739,948 | |
| Median | 1,340,482 | |
| Standard Deviation | 3,408,006 | |
| Sample Variance | 11.6T | |
| Range | 11M | |
| R-Value | 0.12 | |
| Mean Square Error | 12.2T | |
| R-Squared | 0.02 | |
| Significance | 0.64 | |
| Slope | 82,932 | |
| Total Sum of Squares | 185.8T |
Appili Cash History
Stock Overview, Methodology & Data Sources
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada. APPILI THERAPEUTICS is traded on Toronto Stock Exchange in Canada. This stock section frames Appili Therapeutics within its peer set and highlights how fundamentals align with price behavior. Current metrics include P/B of 1.4. Appili Therapeutics has a market cap of 3.03 M, ROE of -9.39%.
Methodology
Unless otherwise specified, financial data for Appili Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Appili (CA:APLI) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Appili Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Appili Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsPair Trading with Appili Therapeutics
Pair trading with Appili Therapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Moving against Appili Stock
| 0.6 | OXY | Occidental Petroleum CDR | PairCorr |
| 0.6 | WHN | Westhaven Ventures | PairCorr |
| 0.58 | ROCK | Rockridge Resources | PairCorr |
| 0.57 | BQE | BQE Water | PairCorr |
| 0.57 | BCE-PR | BCE Inc Pref | PairCorr |
Sophisticated investors use correlation analysis to build Appili Therapeutics replacement strategies that go beyond simple sector matching. Assets with similar factor exposures to Appili Therapeutics provide the most accurate portfolio substitution during tax-loss harvesting periods.
Statistical correlation between Appili Therapeutics and its peers is an essential input for mean-variance portfolio optimization. Lower correlation of Appili Therapeutics with other holdings allows for a more efficient frontier with superior risk-adjusted returns.
Correlation analysis and pair evaluation for Appili Therapeutics can support hedging context. This approach is commonly reviewed within sectors and across broader groups.More Resources for Appili Stock Analysis
Other Information on Investing in Appili Stock
Financial ratios for Appili Therapeutics provide valuation context across profits, cash flow, and enterprise value. They help compare Appili across valuation measures in a consistent way.